ZDA
ANIK icon

Zweig-DiMenna Associates’s Anika Therapeutics ANIK Stock Holding History

Zweig-DiMenna Associates’s Portfolio ANIK Stock Details ANIK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-61,090
Closed -$2.77M – 187
2020
Q4 		$2.77M Hold
61,090
– – 0.18% 110
2020
Q3 		$2.16M Hold
61,090
– – 0.15% 112
2020
Q2 		$2.31M Buy
61,090
+52,390
+602% +$1.73M 0.24% 89
2020
Q1 		$252K Buy
+8,700
New +$352K 0.03% 75

Other funds holding ANIK

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Kayne Anderson Rudnick Investment Management
Kayne Anderson Rudnick Investment Management Los Angeles, California $34B AUM 6.31% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BTW
Boston Trust Walden Boston, Massachusetts $12.2B AUM 12.45% 1-Year Est. Return
FWIA
Fort Washington Investment Advisors Cincinnati, Ohio $18.1B AUM 18.25% 1-Year Est. Return

Zweig-DiMenna Associates's ANIK Position: Q1 2021 in Review

Zweig-DiMenna Associates sold out of Anika Therapeutics (ANIK) in Q1 2021, closing a stake of 61,090 shares — an estimated $2.77M sold.

Zweig-DiMenna Associates first reported a position in ANIK in Q1 2020 and held it in 4 quarters. The position peaked at $2.77M in Q4 2020. 146 funds tracked by Wall St. Rank hold ANIK as of Q1 2021.

  • Zweig-DiMenna Associates reported no remaining Anika Therapeutics position as of Q1 2021 after selling out during the quarter.
  • Zweig-DiMenna Associates sold 61,090 Anika Therapeutics shares in Q1 2021, an estimated $2.77M.
  • Zweig-DiMenna Associates first reported a position in Anika Therapeutics in Q1 2020 and held it in 4 quarters.
  • Zweig-DiMenna Associates's Anika Therapeutics position peaked at $2.77M in Q4 2020.
  • 146 funds tracked by Wall St. Rank held Anika Therapeutics as of Q1 2021.

Based on Zweig-DiMenna Associates's 13F filing for Q1 2021, filed 26 Apr 2021.